Baclofen Treatment of Ataxia Telangiectasia

Key facts

Sponsor

Johns Hopkins University

Principal Investigator

Thomas O Crawford, M.D.

Johns Hopkins School of Medicine

Intervention

Baclofen(drug)

Enrollment

10 enrolled

Eligibility

12 years · All sexes

Timeline

2007 – 2011

Study locations (1)

• Johns Hopkins Hospital, Baltimore, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Ataxia-telangiectasia

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE3NCT06673056
  A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
  IntraBio Inc
• ACTIVE NOT RECRUITINGPHASE2NCT04870866
  NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia
  University Hospital, Akershus

See all trials for Ataxia-telangiectasia →